Rodman & Renshaw Reiterates Acorda Therapeutics Market Underperform, $18 PT

Rodman & Renshaw reiterated its Acorda Therapeutics (ACOR) Market Underperform rating and $18 price target in a research report published today. In the report, Rodman & Renshaw states, "We find no reason to be optimistic about the future of Ampyra, until proven otherwise." Shares of Acorda Therapeutics were trading at $23.13 at the time of posting, up 12.93% from Thursday's market close.